Premier Alternatives

Allotex

Boston, MA · Founded 2014 · Privately Held (backing)

Operator of an ophthalmic biologics and device company intended for the treatment of presbyopia, hyperopia and myopia. Allotex is based in Boston, MA and was founded in 2014. It was valued at $358 million at its early-stage round in Mar 2018, the last priced event on record. It has raised $46.8 million across 1 recorded round; the latest was a $16.7 million early-stage round in Feb 2018.

PMV mark · valuation
$358.0M
Oct 2026
Priced at
its early-stage round
Mar 2018
Total raised
$46.8M
Last round
Early Stage VC
Feb 2018

Allotex key facts

as of Oct 2026
  • Operator of an ophthalmic biologics and device company intended for the treatment of presbyopia, hyperopia and myopia.
  • Allotex is valued at approximately $358.0M as of Oct 2026, set at its early-stage round, Mar 2018; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $46.8M across 1 recorded rounds; the latest was Early Stage VC ($16.7M) in Feb 2018.
  • Notable investors include Supernova Invest, Panakes Partners, Exor, Junson Capital, KCK MedTech — 6 tracked in total.
  • Allotex has filed 1 Form D with the SEC, most recently Mar 2018 ($16.7M sold to 2 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$358.0M

Valued at $358.0M at its early-stage round, Mar 2018. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Allotex with a free account
  • ·Watch Allotex: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Allotex funding rounds

1 rounds
Feb 2018Early Stage VC$16.7MSEC filing▮
Full funding history →

Allotex valuation

Allotex was valued at $358 million at its early-stage round in Mar 2018. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Allotex raised?

Allotex has raised $46.8 million in total; 1 of its rounds is on record. The largest on record was a $16.7 million early-stage round in Feb 2018.

Allotex has filed 1 Form D with the SEC, most recently in Mar 2018 ($16.7 million sold to 2 investors).

Allotex investors

6 investors are on record for Allotex, including Supernova Invest, Panakes Partners, Exor and Junson Capital. The early-stage round in Feb 2018 drew 2 investors.

About Allotex

Operator of an ophthalmic biologics and device company intended for the treatment of presbyopia, hyperopia and myopia. The company uses precisely-shaped human corneal allografts with a compact excimer laser system to create a permanent, living contact lens or lens insert, enabling medical professionals to offer treatment that has the least invasive for all refractive procedures.

Sector
Healthcare
HQ
Boston, MA, United States
Founded
2014
Employees
21
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.